What the FDA labels say about taking them together
Trastuzumab and trastuzumab-strf
Trastuzumab-strf's FDA label of March 21, 2025 names trastuzumab in its boxed warning section; the trastuzumab labels PlainMeds reads (4) do not name trastuzumab-strf. The trastuzumab-strf label: “CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY Cardiomyopathy Administration of trastuzumab products can result in sub-clinical and clinical cardiac failure.”
Check it at the source: the trastuzumab FDA label on DailyMed (effective May 29, 2026, Genentech, Inc.); the trastuzumab-strf FDA label on DailyMed (effective March 21, 2025).
What does the trastuzumab label say about trastuzumab-strf?
Trastuzumab's label (effective May 29, 2026) and its 3 other brand-application labels do not name trastuzumab-strf in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Herceptin), Genentech, Inc., effective May 29, 2026 (SPL set 492dbdb2-077e-4064-bff3-372d6af0a7a2), via openFDA; the full label on DailyMed
What does the trastuzumab-strf label say about trastuzumab?
Trastuzumab-strf label, boxed warningCARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY Cardiomyopathy Administration of trastuzumab products can result in sub-clinical and clinical cardiac failure.
Trastuzumab-strf label, drug interactionsDRUG INTERACTIONS Anthracyclines Patients who receive anthracycline after stopping trastuzumab products may be at increased risk of cardiac dysfunction because of trastuzumab products estimated long washout period [see Clinical Pharmacology (12.3)] If possible, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab products.
Trastuzumab-strf label, warnings and precautionsTrastuzumab products can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death [see Boxed Warning:
Source: FDA drug label (HERCESSI), Accord BioPharma Inc., effective March 21, 2025 (SPL set 285d2142-5bfa-401c-9246-7de21c4451af), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Trastuzumab | Trastuzumab-strf | |
|---|---|---|
| Labeled for | Breast cancer | Breast cancer |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once